Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy - guidance (TA378)
- Source:
- National Institute for Health and Care Excellence - NICE
- Publication date:
- 27 January 2016
Abstract
Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.
Guidance development process
How we develop NICE technology appraisal guidance
Next review date: January 2019